Belite Bio Beats Q1 EPS Estimates, Launches Rolling FDA NDA for Stargardt Treatment
Belite Bio’s Q1 adjusted loss per share was $0.34 beating consensus by $0.30, while GAAP loss per share widened from -$0.45 to -$0.68 on higher R&D and SG&A outlays. The company commenced a rolling FDA NDA submission for tinlarebant in STGD1 and holds $798.6M cash to fund its development strategy.
1. Q1 Financial Performance
Belite Bio reported an adjusted net loss of $13.7 million for Q1 2026, translating to an adjusted loss per share of $0.34, outperforming analyst forecasts by $0.30. On a GAAP basis, net loss widened to $26.9 million, or $0.68 per share, compared with $14.3 million, or $0.45 per share, in Q1 2025.
2. Expense Increases
Research and development expenses rose to $15.7 million from $9.4 million year over year, driven by costs associated with the DRAGON II clinical trial and tinlarebant manufacturing activities. Selling, general and administrative expenses increased to $17.0 million from $6.1 million, reflecting higher share-based compensation, professional services, and expanded staffing.
3. FDA NDA Submission Progress
In April 2026, the company initiated a rolling New Drug Application submission to the FDA for tinlarebant to treat Stargardt disease type 1, with full submission expected in Q2. Belite Bio also completed recruitment for all key commercial leadership roles in preparation for a potential product launch.
4. Cash Position and Liquidity
As of March 31, 2026, Belite Bio held $798.6 million in cash, cash equivalents and U.S. Treasury securities, providing substantial liquidity to fund ongoing clinical trials, regulatory activities, and commercial launch preparations.